Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 8/20 | 0.47 |
| ▸ | PYGM | P11217 | 3/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1055725 | 1.00 | TK2 (0.47) | TK2PYGMP2RY6 | |
| SCHEMBL1060642 | 0.90 | TK2 (0.45) | TK2PYGM | |
| SCHEMBL1060646 | 0.90 | TK2 (0.45) | TK2PYGM | |
| SCHEMBL27179233 | 0.90 | TK2 (0.49) | TK2PYGM | |
| SCHEMBL1060099 | 0.90 | TK2 (0.49) | TK2PYGM | |
| SCHEMBL1060097 | 0.90 | TK2 (0.49) | TK2PYGM | |
| SCHEMBL1061657 | 0.87 | TK2 (0.45) | TK2PYGM | |
| SCHEMBL1061655 | 0.87 | TK2 (0.45) | TK2PYGM | |
| SCHEMBL10591532 | 0.85 | TK2 (0.54) | TK2PYGM | |
| SCHEMBL24229287 | 0.85 | TK2 (0.62) | TK2PYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957201-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-7994145-B2 | Bicyclonucleoside analogues | TAKESHI IMANISHI (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-7816333-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20090149404-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-06-11 | — | — | US | disclosed |
| US-7335765-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-02-26 | — | — | US | disclosed |
| US-7314923-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-01 | — | — | US | disclosed |
| US-20070270370-A1 | Novel bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2007-11-22 | — | — | US | disclosed |
| US-7217805-B2 | Bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2007-05-15 | — | — | US | disclosed |
| US-7002006-B2 | Protection of nucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| WO-2004072234-A2 | PROTECTION OF NUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040158055-A1 | Protection of nucleosides | IONIS PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040143114-A1 | Novel bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2004-07-22 | — | — | US | disclosed |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY, LIMITED (JP) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270370-A1 | Novel bicyclonucleoside analogues | PURB, RNGTT, NSUN2 | TK2 231/4885PYGM 3555/4885P2RY6 358/4885 |
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | TK2 65/4885PYGM 1467/4885P2RY6 1164/4885 |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | TK2 447/4885PYGM 2644/4885P2RY6 237/4885 |
| US-20090149404-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | TK2 65/4885PYGM 1467/4885P2RY6 1164/4885 |
| US-20040158055-A1 | Protection of nucleosides | RNASEL, ADAR, RNGTT | TK2 259/4885PYGM 1359/4885P2RY6 377/4885 |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | TK2 447/4885PYGM 2644/4885P2RY6 237/4885 |
| US-20040143114-A1 | Novel bicyclonucleoside analogues | PURB, DUT, NSUN2 | TK2 205/4885PYGM 3895/4885P2RY6 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.